EPP

(redirected from erythropoietic protoporphyria)
Also found in: Dictionary, Medical, Wikipedia.
Related to erythropoietic protoporphyria: erythropoietic porphyria

EPP

EPP

(1) (Enhanced Parallel Port) See IEEE 1284.

(2) (Easy Photo Print) A mobile application from Canon that lets users print wireless from their smartphones and tablets to their Canon printers.

(3) (Ethernet Packet Processor) A chip from Kalpana, Inc., Santa Clara, CA that doubles speed of Ethernet transmission to 20Mbits/sec. In 1994, Kalpana was acquired by Cisco.
References in periodicals archive ?
Erythropoietic protoporphyria (EPP), a rare inborn error of metabolism that usually manifests in early childhood as severe photosensitivity, causes excruciating pain 1-20 minutes after exposure to the sun.
The product has received approval based on clinical trials conducted in 350 adult erythropoietic protoporphyria patients.
Molecular characterization of erythropoietic protoporphyria in South Africa.
Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics.
All laboratories submitting results for erythrocyte protoporphyrin fractions found predominantly free protoporphyrin in the erythropoietic protoporphyria (EPP) patient.
Others like congenital erythropoietic porphyria (CEP), porphyria cutanea tarda (PCT), and erythropoietic protoporphyria deal with skin photosensitivity (1,3).
Erythropoietic protoporphyria (EPP) is an autosomal dominant defect in haem synthesis caused by defective ferrochelatase; the terminal enzyme.
GOTHENBURG, SWEDEN -- A resorbable subcutaneous implant of afamelanotide significantly reduced painful phototoxic attacks in patients with erythropoietic protoporphyria in a year-long multinational clinical trial.
Clinuvel Pharmaceuticals achieved positive results from a Phase III trial of Scenesse in patients with erythropoietic protoporphyria (EPP), showing that the drug has the ability to reduce and prevent painful phototoxic reactions.
Tia's incurable condition was noticed at one -though doctors disagreed on a diagnosis before she was found to have rare erythropoietic protoporphyria (EPP).
Results released today from a Phase III trial of the drug SCENESSE (R), conducted by Melbourne-based Clinuvel Pharmaceuticals Limited (ASX:CUV) (PINK:CLVLY), have shown that the drug has the ability to reduce and prevent painful phototoxic reactions experienced by patients with erythropoietic protoporphyria (EPP).
Beta-carotene as a protective agent in erythropoietic protoporphyria.

Full browser ?